Rhabdoid tumor

This early-phase trial tests a new treatment for children and young adults with medulloblastoma or similar brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to recognize and attack tumor cells, deliv…

This early-stage trial tests whether using focused ultrasound with microbubbles can temporarily open the blood-brain barrier, allowing the immunotherapy drug nivolumab to reach brain tumors more effectively. It includes 30 children and young adults with relapsed diffuse midline g…

This early-stage trial tests whether a specially engineered herpes virus (G207) is safe to inject directly into the brain tumors of children whose cancer has returned. Up to 24 children aged 3 to 21 will receive the virus, and some will also get a small dose of radiation to help …

This early-phase study tests the safety of a new cell therapy called B7-H3 CAR T cells for children and young adults whose brain tumors have come back or are growing despite standard treatment. The therapy uses the patient's own immune cells, modified to target a protein (B7-H3) …

This study tests two oral drugs, eflornithine (DFMO) and AMXT 1501, in children and young adults up to age 26 with certain cancers that have come back or not responded to treatment. The cancers include neuroblastoma, brain tumors, and sarcomas. The goal is to find a safe dose and…

This early-phase trial tests a new immunotherapy called CARE T cells in children and young adults with solid tumors that have returned or not responded to standard treatment. The cells are taken from the patient, genetically modified to recognize a protein (GPC3) found on many so…

This phase 2 trial is testing the immunotherapy drug nivolumab in 23 people aged 1 year and older with advanced or recurrent rhabdoid tumors that have not responded to chemotherapy. The goal is to see if the drug can shrink tumors and improve survival. Participants receive nivolu…

This early-phase trial tests a new type of immune therapy for people with certain aggressive brain tumors, including DIPG and high-grade glioma. The treatment uses the patient's own T cells, which are modified in the lab to recognize a protein called GD2 on cancer cells and to pr…

This early-phase study tests whether adding chemotherapy directly into the spinal fluid (intrathecal topotecan) followed by maintenance pills is feasible for children under 6 with high-risk embryonal brain tumors. About 15 children will receive this treatment after standard high-…

This phase 1 trial tests a drug called 177Lu-DTPA-omburtamab, which delivers radiation directly to tumor cells in children and teens with recurrent or refractory medulloblastoma or other central nervous system (CNS) tumors that have spread. The drug targets a protein called B7-H3…

This study tests a special stem cell transplant for children, teens, and young adults (ages 6 months to 25 years) with solid tumors that have come back or not responded to treatment. The transplant uses cells from a donor, with certain immune cells removed to reduce side effects,…

This study tests a combination of two drugs, gemcitabine and paxalisib, in children, teens, and young adults whose atypical teratoid rhabdoid tumor (ATRT) has come back or gotten worse. The goal is to find a safe dose and see if the drugs can control the tumor. About 29 participa…

This early-stage trial tests whether personalized immune cells (T-cells) can safely treat young children with aggressive brain tumors. The T-cells are designed to attack unique markers found on each child's tumor. Up to 12 children under 5 with embryonal brain tumors or recurrent…

This study is testing a combination of four drugs—atezolizumab, sorafenib, bevacizumab, and cyclophosphamide—in children and young adults with solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the combination can sh…

This study is for children and young adults (ages 1 to 30) whose solid tumors have come back or not gone away with standard treatment. It tests two different drug pairs: one combines Onivyde with talazoparib, the other Onivyde with temozolomide. Both work by damaging cancer cell …

This early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…

This study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain solid tumors that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug is safe and to find the best dose, while a…

This phase II trial is testing the drug selinexor in people with Wilms tumor, rhabdoid tumor, MPNST, or other solid tumors that have returned or not responded to treatment. Selinexor works by blocking a protein called XPO1, which is often overactive in these cancers. The study ai…

This early-phase study tests whether a new type of immunotherapy, called B7-H3 CAR T cells, can be safely given directly into the brain or spinal fluid of children and young adults with aggressive brain tumors like DIPG, DMG, or other recurrent central nervous system cancers. The…

This phase 2 trial tests whether a year-long maintenance regimen of sirolimus (rapamycin) plus low-dose oral chemotherapy and celecoxib can improve 2-year survival without cancer progression in children with high-risk solid tumors. About 55 children and young adults (ages 1–30) w…

This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells, which are genetically modified in the lab to recognize and attack cancer cells…

This early-phase trial tests a new type of immunotherapy for adults with solid tumors that have a protein called GPC3 on their surface. Researchers take a patient's own T cells, add genes to help them recognize and attack GPC3-positive cancer cells, and also include a safety swit…

This study is collecting genetic and molecular data from up to 1,600 children with liver cancer and their families. Researchers will analyze DNA, gene activity, and immune cells to better understand what drives these rare tumors. The goal is to improve how these cancers are class…